Karyopharm Therapeutics Inc.
Close on Oct 19, 2026
- Market cap
- $10.01K
- P/E (TTM)
- –
- Dividend yield
- –
About Karyopharm Therapeutics
Pharmaceutical Preparations, SIC 2834
Karyopharm Therapeutics Inc. is a pharmaceutical company that focuses on the discovery, development, and commercialization of treatments such as Xpovio. Operating within the healthcare sector, the business develops product candidates and enters into commercial collaborations and licensing agreements with partner firms, including Menarini and Antengene Therapeutics. Through these arrangements, the company provides products and licenses its pharmaceutical assets to partners and customers across the industry.
The company maintains operational activities in the United States and works with international licensing partners. Its principal executive offices and headquarters are located at 85 Wells Avenue, 2nd Floor, in Newton, Massachusetts. In addition, the organization leases dedicated office and research space to conduct its operations and support its business initiatives.
Summary of the business section of Karyopharm Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Karyopharm Therapeutics Inc.
- Founded
- 2008
- Headquarters
- Newton, MA
- Address
- 85 Wells Avenue, Second Floor 02459
- Phone
- (617) 658-0600
- Website
- karyopharm.com
- Employees
- 228, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- KPTI
- Exchange
- Nasdaq
- IPO date
- Nov 7, 2013
- Shares outstanding
- 23M, Aug 6, 2026
- Public float
- $37.00M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-15 reverse, May 12, 2025; 1-for-15 reverse, Feb 26, 2025
- SEC CIK
- 1503802
- CUSIP
- 48576U205
- ISIN
- US48576U2050
- LEI
- 549300J1VANRCNTYST87
- EIN
- 26-3931704
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Richard A. Paulson | President and CEO, Director | 269,747 |
| Kristin Abate | Chief Accounting Officer | 23,782 |
| Stuart Poulton | EVP, Chief Development Officer | 94,632 |
| Reshma Rangwala | EVP & Chief Medical Officer | 56,829 |
| Sohanya Roshan Cheng | EVP & Chief Commercial Officer | 107,940 |
| Michael Mano | EVP, CLO&Secretary | 94,398 |
| Lori Macomber | EVP, CFO & Treasurer | 85,105 |
| Christy J. Oliger | Director | 15,508 |
| Chen Schor | Director | 15,508 |
| Barry E. Greene | Director | 16,415 |
| Garen G. Bohlin | Director | 18,517 |
| Deepika Pakianathan | Director | 15,508 |
| Zhen Su | Director | 15,508 |
| Mansoor Raza Mirza | Director | 17,121 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr. Paulson | $2.32M | $2.12M | $1.71M | $14 | – |
| FY2024 Mr. Paulson | $2.07M | $1.65M | $1.11M | $20 | – |
| FY2023 Mr Paulson | $2.63M | $35.74K | $1.17M | $25 | – |
| FY2023 Mr. Paulson | $2.63M | $35.74K | $1.17M | $25 | – |
| FY2022 Dr Kauffman | $0 | $0 | $2.89M | $53 | – |
| FY2022 Mr Paulson | $6.91M | $1.56M | $2.89M | $53 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of February 5, 2026, we had 228 employees, all of whom were full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 17, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Dec 12, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 17, 2014 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Nov 7, 2013 | IPO | Initial public offering priced (424B4 prospectus) |
| Nov 1, 2013 | Listing | Registration of securities on an exchange (Form 8-A) |